Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Brexit Leaves U.S. Regulatory Attorneys With Many Questions

June 27, 2016, The Legal Intelligencer

Grant Castle is quoted in a Legal Intelligencer article regarding the regulatory impact of Brexit. Commenting on the Food and Drug sector, Castle says, “The UK will inevitably diminish in significance when it comes to the regulation of pharmaceuticals and a venue where drug companies are going to want to be based. Historically, U.S. companies wanted to operate in Europe, out of the UK, primarily. We speak the language, we have the main EU regulator. So if you're looking at Europe from a policy, regulation perspective, you're going to be wanting to think about how the diminution of the UK as a player in the EU and globally will affect corporate structures and affect the pharmaceutical supply chain."

Share this article: